[Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma]

Ophthalmologe. 2006 Jun;103(6):506-11. doi: 10.1007/s00347-006-1350-7.
[Article in German]


Purpose: In this manuscript, the safety and efficacy of adjuvant interferon alfa 2b treatment of uveal melanoma is described.

Patients and methods: A total of 39 patients (23 male and 16 female, mean age 56.5 years, range 35-78 years) with uveal melanoma were treated with interferon alfa 2b, 3 million units three times a week subcutaneously for 1 year after therapy of the primary tumor. In all patients age, gender, primary melanoma data, therapeutic interventions, treatment side effects and outcome were documented.

Results: Of the 39 patients, 31 (80%) finished the treatment as scheduled after 1 year. In 18 patients (46%) the initial dose had to be reduced due to leucopenia, thrombopenia, cardiac symptoms, elevated of liver function or vertigo (WHO grade I-III). In eight patients, therapy had to be withdrawn because of serious side effects (five patients) and the appearance of metastases (three patients). Neither a univariate approach nor a multivariate approach could show a protective effect of interferon treatment on survival.

Conclusions: Adjuvant treatment of uveal melanoma with interferon alfa should be abandoned until the question of dose and administration for cutaneous melanoma is solved.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage*
  • Interferon-alpha / adverse effects*
  • Male
  • Melanoma / drug therapy*
  • Middle Aged
  • Recombinant Proteins
  • Risk Assessment / methods*
  • Risk Factors
  • Treatment Outcome
  • Uveal Neoplasms / drug therapy*


  • Antineoplastic Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins